VitaNova Life Sciences Corporation reported sharply higher sales but moved into a small loss for the quarter and nine months ended January 31, 2026. Revenue reached $709,625 for the quarter and $1,240,639 for nine months, increases of 130% and 75% driven by its dietary supplement segment. Gross profit rose, but margins narrowed as cost of revenue grew faster than sales and general and administrative expenses climbed to $405,339 for nine months, largely from higher legal and professional fees. The company posted net losses of $44,362 for the quarter and $54,853 year‑to‑date, compared with profits a year earlier, and recorded an effective tax rate above the statutory level. Cash improved to $1,168,904 with operating cash flow of $386,094, and shareholders’ equity was $1,853,831 with 8,337,454 common shares outstanding as of March 11, 2026. Management highlights continued material weaknesses in internal controls and a high dependence on a few customers and a single vendor, while also noting a recent name change, a 1‑for‑3 reverse stock split, and formation of a new wholly owned subsidiary, VitaNova Global Foods Corporation.
VitaNova Life Sciences Corporation added its Chief Financial Officer, Steve Niu, to the Board of Directors effective February 19, 2026. He will serve as a director until the next annual stockholder meeting or earlier resignation or removal and will not receive additional compensation for this role.
The Board determined that Mr. Niu does not qualify as an independent director under Nasdaq corporate governance standards. He has served as VitaNova’s CFO since January 2024 and previously was President of Triangle Accounting, Inc. from 2001 to 2024, with extensive experience in U.S. and international taxation and regulatory compliance.